In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile

OBJECTIVES: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). The objective was to determine the comparative susceptibility of 82 C. difficile clinical isolates (which included ribotype 027 isolates and isolates with reduced metr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Antimicrob Chemother
Egile Nagusiak: Corbett, D., Wise, A., Birchall, S., Warn, P., Baines, S. D., Crowther, G., Freeman, J., Chilton, C. H., Vernon, J., Wilcox, M. H., Vickers, R. J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4498293/
https://ncbi.nlm.nih.gov/pubmed/25652750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak